Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.2701-0.0049 (-1.78%)
At close: 12:59PM EST
0.2750 +0.00 (+1.81%)
After hours: 02:07PM EST
Advertisement
Full screen
Loading interactive chart...
  • Business Wire

    Kiromic BioPharma Arranges Up to $10 Million Financing

    HOUSTON, October 27, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD, a partnership managed by Yorkville Advisors Global LP, a global investment manager, to sell up to $8 mi

  • Benzinga

    Kiromic Shares Surge After Streamlining Operations To Execute Deltacel-Aligned Development Strategy

    Kiromic BioPharma Inc (NASDAQ: KRBP) received validating written feedback from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel development strategy. Deltacel is the company's most advanced therapeutic candidate, applying in allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cells (GDT). The Pre-IND meeting request was to align with and obtain FDA guidance on Kiromic's proposed development strategy about the chemistry, manufacturing, and controls (CMC)

  • Business Wire

    Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

    HOUSTON, October 06, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.

Advertisement
Advertisement